US 12,358,949 B2
Defensin fragments for use in therapy or prophylaxis
Jan Wehkamp, Reutlingen (DE); and Dirk Ehmann, Tübingen (DE)
Assigned to Aesculus Bio ApS, Copenhagen N (DK)
Appl. No. 17/420,155
Filed by Aesculus Bio ApS, Copenhagen N (DK)
PCT Filed Jan. 7, 2020, PCT No. PCT/EP2020/050186
§ 371(c)(1), (2) Date Jul. 1, 2021,
PCT Pub. No. WO2020/144166, PCT Pub. Date Jul. 16, 2020.
Claims priority of application No. 102019100230.3 (DE), filed on Jan. 7, 2019; and application No. 102019108626.4 (DE), filed on Apr. 2, 2019.
Prior Publication US 2022/0064217 A1, Mar. 3, 2022
Int. Cl. C07K 7/08 (2006.01); A61K 38/00 (2006.01)
CPC C07K 7/08 (2013.01) [A61K 38/00 (2013.01)] 13 Claims
 
1. A peptide having antimicrobial activity, which peptide is a fragment of human defensin-5 (HD-5) or a fragment of human neutrophil peptide 4 (HNP-4), wherein the peptide consists of the sequence of:
 
 (SEQ ID No: 1)
 
 ATCYCRTGR,
 
 
 
 (SEQ ID No: 2)
 
 RGTRCYCTA,
 
 
 
 (SEQ ID No: 5)
 
 Ac-atcycrtGr-NH2,
 
 
 
 (SEQ ID No: 3)
 
 VCSCRLVFCRR,
 
 
 
 (SEQ ID No: 4)
 
 RRCFVLRCSCV,
 
 
 
 (SEQ ID No: 6)
 
 Ac-vcscrlvfcrr-NH2
 
 
 
 (SEQ ID No: 41)
 
 LYRLCCR,
 
 
 
 (SEQ ID No: 34)
 
 ATCYCRTGRCATR,
 
 
 
 (SEQ ID No: 12)
 
 ATCYCRTGRCATRESLSGVCEISGRLYR,
 
 
 
 (SEQ ID No: 14)
 
 TGRCATRESLSGVCEISGRLYRLCCR,
 
 
 
 (SEQ ID No: 19)
 
 CATRESLSGVCEISGRLYRLCCR,
 
 
 
 (SEQ ID No: 25)
 
 ESLSGVCEISGRLYRLCCR,
 
 
 
 (SEQ ID No: 28)
 
 CATRESLSGVCEISGRLY,
or multimers thereof, or N- or C-terminal non-amino acid modifications thereof.